Baricitinib phosphate salt

CHF 198.00
In stock
SYN-1117-M0011 mgCHF 198.00
SYN-1117-M0055 mgCHF 329.00
SYN-1117-M01010 mgCHF 461.00
SYN-1117-M05050 mgCHF 1'383.00
SYN-1117-M100100 mgCHF 2'304.00
 
More Information
Product Details
Synonyms LY-3009104; INCB-28050
Product Type Chemical
Properties
Formula C16H17N7O2S . H3PO4
MW 371.4 . 98.0
CAS 1187595-84-1
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO or ethanol.
Declaration Manufactured by SynKinase.
Other Product Data Target: JAK | Kinase Group: PTK | Substrate: Tyrosine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key FBPOWTFFUBBKBB-UHFFFAOYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Baricitinib is a selective JAK1 and JAK2 inhibitor. IC(50) values are 5.9nm for JAK1, and 5.7nM for JAK2. In cell based assays Baricitinib/INCB-28050 demonstrated inhibition of intracellular signaling of multiple pro-inflammatory cytokines including IL-6 and IL-23 at concentrations of < 50nM, and also showed good efficacy in a number of animal models at doses of 10mg/kg and below. Baricitinib is in Phase III development as a potential treatment for rheumatoid arthritis. It is in Phase II development as a potential treatment for psoriasis and diabetic nephropathy
Product References
  1. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050: J.S. Fridman, et al.; J. Immunol. 184, 5298 (2010)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.